In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast","authorlink":""},"src":"https:\/\/traffic.libsyn.com\/secure\/helixtalk\/035_-_Empagliflozin_and_dulaglutide.mp3?dest-id=187168","thumb":{"src":"https:\/\/images.lystnfm.com\/tr:n-app_thumbnail_medium\/podcastsnw-202310\/51d8ce-5810-087d-300941_800.png"},"title":"035 - Empagliflozin and dulaglutide","link":"javascript:;","id":"item-685470"}]
